Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Marek’s disease virus antigens refer to a collection of proteins encoded by Marek’s disease virus (MDV), an alphaherpesvirus that infects chickens and causes T-cell lymphomas and immunosuppression. Notable antigens include the phosphoprotein pp38 (associated with viral transformation and always present in transformed cells), the Meq oncoprotein (homologous to the Jun/Fos family and essential for tumor development), and envelope glycoprotein C (gC, important for viral spread and immune evasion). These antigens serve as important immunological and diagnostics markers, and form the basis for vaccine development, but they do not correspond to a single therapeutic target like a host receptor or enzyme. The term "Marek's disease virus antigens" is therefore too broad and imprecise for structured target information, as it encompasses multiple proteins with divergent molecular features and functions, rather than a single defined target molecule.
Not applicable for drugs, but for vaccines: induction of protective immune responses (mainly via live-attenuated vaccines, which present MDV antigens to elicit immunity)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Marek’s disease virus antigen (MDV antigen).